X4 Pharmaceuticals (XFOR) will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on September 10, 2026, at 9:30 a.m. ET.
A live and archived webcast will be available via the Investors > Events and Presentations section of the company’s website. X4 develops therapies for rare hematology diseases and has commercialized mavorixafor (XOLREMDI) in the U.S., with a global pivotal Phase 3 4WARD trial in chronic neutropenic disorders and FDA Fast Track designation for chronic neutropenia.
"mavorixafor, an orally available CXCR4 antagonist"
A CXCR4 antagonist is a medicine that blocks a specific cell surface receptor called CXCR4, stopping signals that guide cell movement and survival. Think of it like putting a padlock on a door that cancer cells or immune cells use to travel and hide; this can slow tumor spread, help release stem cells for transplant, or interfere with viruses. For investors, drugs using this mechanism can create clear clinical milestones, niche market opportunities, and regulatory risks tied to trial results.
phase 3 clinical trialmedical
"currently conducting a global, pivotal Phase 3 clinical trial"
A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.
fast track designationregulatory
"The U.S. FDA has granted Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
chronic neutropeniamedical
"for the treatment of chronic neutropenia"
A long-lasting medical condition in which the blood has an abnormally low number of neutrophils, a type of white blood cell that acts like the body’s first responders against bacterial and fungal infections. Because it raises the risk of recurrent or severe infections and often requires ongoing monitoring, treatments, or preventive measures, chronic neutropenia is important to investors in healthcare and biotech as it affects clinical trial design, regulatory requirements, market need for therapies, and potential product safety or liability considerations.
BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET.
A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations.
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
How can investors access the X4 Pharmaceuticals fireside chat webcast?
The live and archived webcast of the fireside chat will be accessible on X4 Pharmaceuticals’ website under the Investors section, in Events and Presentations.
What is X4 Pharmaceuticals’ lead therapy and its development status?
X4 has developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI in its first indication and is being evaluated in a global, pivotal Phase 3 4WARD trial for chronic neutropenic disorders. The U.S. FDA has granted mavorixafor Fast Track designation for the treatment of chronic neutropenia.
